- Research article
- Open Access
Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000
BMC Pharmacology volume 8, Article number: 20 (2008)
A series of 1H-imidazo- [4,5-c]quinolin-4-amine derivatives, represented by LUF6000 (N-(3,4-dichloro-phenyl)-2-cyclohexyl-1H-imidazo [4,5-c]quinolin-4-amine), are allosteric modulators of the human A3 adenosine receptor (AR). Here we studied the modulation by LUF6000 of the maximum effect (Emax) of structurally diverse agonists at the A3 AR stably expressed in CHO cells.
In an assay of [35S]GTPγS binding, the Emax of the A3 AR agonist Cl-IB-MECA at the A3 AR was lower than that of the non-selective AR agonist NECA. LUF6000 exerted an Emax-enhancing effect at a concentration of 0.1 μM or higher, and was shown to increase the Emax of Cl-IB-MECA and other low-efficacy agonists to a larger extent than that of the high-efficacy agonist NECA. Interestingly, LUF6000 converted a nucleoside A3 AR antagonist MRS542, but not a non-nucleoside antagonist MRS1220, into an agonist. LUF6000 alone did not show any effect. Mathematical modeling was performed to explain the differential effects of LUF6000 on agonists with various Emax. A simple explanation for the observation that LUF6000 has a much stronger effect on Cl-IB-MECA than on NECA derived from the mathematical modeling is that NECA has relatively strong intrinsic efficacy, such that the response is already close to the maximum response. Therefore, LUF6000 cannot enhance Emax much further.
LUF6000 was found to be an allosteric enhancer of Emax of structurally diverse agonists at the A3 AR, being more effective for low-Emax agonists than for high-Emax agonists. LUF6000 was demonstrated to convert an antagonist into an agonist, which represents the first example in G protein-coupled receptors. The observations from the present study are consistent with that predicted by mathematical modeling.
Adenosine receptors (ARs) are G protein-coupled receptors, consisting of A1, A2A, A2B and A3 subtypes, activated by the endogenous agonist adenosine and blocked by natural antagonists, such as caffeine and theophylline. A1 and A3 subtypes are coupled to Gi/o proteins, while A2A and A2B subtypes are Gs protein-coupled. There is growing evidence that they could be promising therapeutic targets in a wide range of conditions [1–3].
Subtype-selective AR agonists have been developed, however, the selectivity for some organs or tissues is nearly unachievable using orthosteric agonists that act directly at the principal ligand binding site of the receptor. This is due to the wide distribution of ARs and, indeed, a number of agonists were discontinued after the initial phases of clinical trials [3–5]. In contrast to directly-acting agonists, allosteric modulators act at a distinct site on the receptor protein to modulate the effect of a native agonist [6–10]. An advantage of an allosteric enhancer of a GPCR over its native, orthosteric activator is that greater selectivity can be achieved. This is due to allosteric sites being generally less conserved than the orthosteric site in a particular receptor family . Furthermore, the allosteric enhancer would enhance the action of the native agonist, but may have no effect of its own on the unoccupied receptor. Thus, the effect of an endogenous agonist, which may be insufficient in a particular disease state, may be magnified in a temporally and spatially specific manner through allosteric modulation.
Allosteric modulation of membrane receptors is best characterized in ligand-gated ion channels. The allosteric enhancer diazepam, which enhances the CNS inhibitory function of the endogenous γ-aminobutyric acid, is a prototypic representative of the benzodiazepines, the most widely prescribed sleep medications. In the GPCR field, cinacalcet, an allosteric enhancer of the calcium-sensing receptor (CaR), has recently been approved for the treatment of secondary hyperparathyroidism in dialysis patients suffering from chronic kidney disease . In the case of ARs, the A1 AR has been the most studied in this context, and one of its allosteric enhancers, T62 (2-amino-4,5,6,7-tetrahydrobenzo [b]thiophen-3-yl-(4-chlorophenyl)methanone), has been in clinical trials for the treatment of neuropathic pain. Numerous allosteric enhancers and inhibitors for Class B and Class C GPCRs are also in various phases of clinical trials for treatment of a number of disorders [7, 10, 12–14].
Allosteric modulators for the A3 AR have been recently identified and characterized . One class of these allosteric modulators, including the 1H-imidazo- [4,5-c]quinolin-4-amine derivative DU124183, was found to decrease agonist potency while enhancing its maximum effect (Emax) . Recently, a new series of the imidazoquinoline derivatives has been synthesized . Several of those allosteric modulators, represented by LUF6000, were found to also enhance Emax but without affecting agonist potency. Thus, the pharmacological profile as a positive allosteric modulator of the A3 AR was superior to that of DU124183. In this study, we extended our previous observations by studying the nature of the potentially flexible modulation by LUF6000 of the agonists with a selection of A3 AR agonists having a distribution of Emax values in A3 AR-expressing CHO cells using a [35S]GTPγS binding assay . We learned that the degree of allosteric enhancement is dependent on the orthosteric ligand examined, which was quantified using a mathematical model , adding further subtlety to this new concept of GPCR regulation.
AR agonists and allosteric modulators used in the present study
A number of nucleoside agonists and one non-nucleoside agonist (LUF5833) used in the present study are shown in Figure 1. The 5' -substituted adenosine derivative NECA is a high-efficacy AR agonist. Medium or low efficacy agonists include: an N6,2,5' -trisubstituted derivative Cl-IB-MECA, a N6-monosubstituted adenosine derivative MRS541, and a non-nucleoside agonist, LUF5833. In addition to agonists, a nucleoside A3 AR antagonist (as defined previously in adenylyl cyclase assays), MRS542,  and a non-nucleoside antagonist MRS1220 were also included. The allosteric modulator (Figure 1) used in the present study is the imidazoquinoline derivative LUF6000, which has been shown to retard agonist radioligand dissociation and to increase agonist Emax, as demonstrated using a cyclic AMP functional assay . LUF6000 was relatively potent as an enhancer of A3 AR agonist activity in comparison to its A3 AR antagonistic properties. It did not bind appreciably at the other subtypes of ARs.
Effects of LUF6000 on the Emax at the A3 AR of agonists with diverse structures studied with a [35S]GTPγS binding assay
The modulation by LUF6000 of the Emax of diverse agonists at the A3 AR was studied using a [35S]GTPγS binding assay, which directly reflects activation of Gi/o proteins. We first compared the Emax-enhancing effects of LUF6000 under several experimental conditions: (a) addition of the enhancer LUF6000 and an agonist Cl-IB-MECA simultaneously (Figure 2A); (b) pre-incubation of the enhancer LUF6000 with membranes for 20 min before the addition of the agonist to be incubated for another 30 min (Figure 2B); (c) pre-incubation of membranes with both LUF6000 and an agonist for 30 min (Figure 2C). It was found that LUF6000, at the concentration of 0.1 μM or higher, produced a similar enhancement of the Emax of Cl-IB-MECA under all of these conditions. Thus, the subsequent experiments were performed without the pre-incubation of LUF6000 and/or agonist with membranes. Also, a longer incubation time (90 min) did not cause further stimulation, but increased the non-specific binding (data not shown). The potency and Emax of Cl-IB-MECA to stimulate [35S]GTPγS binding in the absence and presence of various concentrations of LUF6000 are summarized in Table 1.
LUF6000 had a less pronounced effect on the Emax of NECA (Figure 2D), but showed a much larger effect on the low-efficacy agonist MRS541 (Figure 2E) compared with its effect on Cl-IB-MECA. MRS542, which has been shown to be an antagonist previously as demonstrated in a cyclic AMP assay , was also demonstrated to be an antagonist in the present GTPγS binding assay (Figure 3A and Figure 3B). However, interestingly, MRS542 was converted into an agonist by LUF6000 in a concentration-dependent manner (Figure 2F). Additionally, LUF6000 also enhanced the stimulation of [35S]GTPγS binding induced by the non-nucleoside agonist, LUF5833 (Figure 3E), whereas it had no effect on the non-nucleoside antagonists MRS1220 (Figure 3C) and MRS1191 (Figure 3D). LUF6000, at concentrations from 0.1 to 10 μM, did not show any effect on the basal level of A3 AR activation in this [35S]GTPγS assay (Figure 3F). The potency and Emax of various ligands in the absence and presence of various concentrations of LUF6000 are summarized in Table 1. The dose-response curves of NECA, Cl-IB-MECA, MRS541, LUF6000 and MRS542 are shown in Figure 3F. Cl-IB-MECA is only partially efficacious compared with NECA in inducing [35S]GTPγS binding.
In order to confirm the effect of LUF6000 on the Emax of the selective agonist Cl-IB-MECA at the A3 AR, we further tested its effect on two other A3 AR selective agonists, IB-MECA and inosine. It was demonstrated that IB-MECA was almost as efficacious as Cl-IB-MECA, and LUF6000 showed similar effect on these two A3 AR agonists. Inosine only showed a low Emax (< 10% of that of NECA). However, in the presence of 10 μM LUF6000, the Emax of inosine was shown to be approximately 80% of the Emax of NECA.
Unlike its effect on the A3 AR, LUF6000 did not affect the Emax of two high-efficacy agonists CPA and CCPA or a low efficacy agonist MRS541 to activate the A1 AR (Figure 4).
The equations from Hall  were used to simulate various experimental curves and to derive conditions in which Emax and EC50 vary. Parameters in these equations are as follows. L is the receptor isomerization constant (the ratio of receptor in the active state over the inactive state). K is the equilibrium association constant of ligand A. M is the equilibrium association constant of ligand B (allosteric modulator). α is the intrinsic efficacy of ligand A. β is the intrinsic efficacy of ligand B. γ is the binding cooperativity between A and B. δ is the activation cooperativity between A and B. L is only related to the receptor. The allosteric modulator brings three parameters, β, γ and δ, to the system. The proportion of receptors in the active state is:
This can be restated as:
Since LUF6000 did not affect the function of the A3 AR when given alone, we concluded it has neutral intrinsic efficacy (β = 1). Next we derived the conditions under which the maximal effect (Emax) and observed potency of an agonist can change in the presence of an allosteric modulator. When there is a saturating concentration of agonist in the absence of allosteric modulator, the proportion of active receptor populations over all receptors is given by:
When there is also an excess amount of allosteric modulator, the proportion is given as:
Comparing these two equations, we learned that if
δ > 1, the maximum response increases;
δ = 1, the maximum response remains unchanged;
δ < 1, the maximum response decreases;
Based on Hall's model of allosteric modulation, the agonist affinity ratio in the presence and absence of an allosteric modulator with neutral intrinsic efficacy is:
We also analyzed the condition in which an allosteric modulator converts a neutral antagonist or even an inverse agonist into an agonist. In the presence of excess amount of an allosteric modulator, the window, i.e. difference in Emax, observed in the absence and presence of a ligand in the orthosteric site is
When αδ > 1, agonism is observed. This implies that when δ, the parameter for activation cooperativity, is large enough, an allosteric modulator can convert a neutral antagonist and an inverse agonist into agonists.
We simulated a number of experimental concentration-effect curves as depicted in Figure 2, reflecting the use of different agonists (Figure 5). We only varied the intrinsic efficacy (α) of the orthosteric ligand A, i.e. for NECA, Cl-IB-MECA, MRS541 and MRS542 α values were set to 500, 100, 50 and 5, respectivly. The values of the other parameters were as follows: L = 0.005; K = 1 × 108; M = 5 × 106; β = 1; γ = 0.05; δ = 50; As is evident from Figure 5, these settings allow for a simulation of concentration-effect curves that closely resemble the ones obtained experimentally.
The result that LUF6000 alone did not show any agonist activity indicates that, under physiological conditions where the concentration of native adenosine is relatively low, LUF6000 should have no effect. The fact that LUF6000 showed significant enhancement of the Emax of agonists, suggests that it could enhance agonist efficacy under some pathophysiological conditions such as ischemia and inflammation where concentrations of endogenous agonists are highly elevated.
It is interesting that LUF6000 was shown to enhance the Emax of low-efficacy agonists to a larger extent than that of the high-efficacy agonists. Furthermore, LUF6000 was demonstrated to be able to convert a nucleoside antagonist MRS542 into an agonist. The effect did not occur with the non-nucleoside antagonists MRS1220 and MRS1191. This may suggest that the nucleoside antagonist may have a small residual activity that would normally be below the detection threshold but could be greatly magnified in the presence of LUF6000.
The ability of GPCRs to adopt various conformational states, each with distinct pharmacological properties, and the phenomenon of stabilization of a specific conformation of a GPCR by an allosteric enhancer have been well documented [9, 21].
Activation of a given GPCR could be accomplished with an allosteric agonist, in addition an orthosteric agonist [10, 22–28]. Conversion of antagonists into agonists has been demonstrated previously by site-directed mutagenesis of GPCRs [29–33] or by chemical modification of the antagonists [20, 34]. However, to our knowledge, there has not been a report regarding this type of conversion by an allosteric modulator, although an example of the conversion of an agonist into antagonist by an allosteric modulator has been reported previously . Thus, it is likely that our finding that an allosteric enhancer can convert an apparent antagonist into an agonist may be generalized to other GPCRs. A better understanding of the conformational states and the mechanisms of GPCR activation will facilitate the design of more effective and selective drugs.
A simple R⇔R* model representing the two conformational states (inactive R, and active R*) of the receptor has been previously used to rationalize the effect of the A1 AR enhancer PD81,723 . PD81,723 alone behaves as an allosteric agonist, promoting the A1 AR to its active conformation (R*) and, thus, potentiates the A1 AR constitutive receptor activity. However, LUF6000 alone does not activate the A3 AR. Thus, unlike PD81,723, which shifts the receptor to the R* state directly, LUF6000 presumably does not cause such a shift.
An extension of the two-state model of receptor activation has been described by Hall  to account for the allosteric modulators affecting the agonist potency as well as the intrinsic efficacy of agonists. Hall  suggested that the most suitable assay system may be one with very low receptor expression in which even highly efficacious agonists are unable to fully activate the signal transduction cascade. We have previously described that our cyclic AMP functional assay system is an ideal model for the characterization of the functional aspects of this class of allosteric modulators, especially the characterization of their effects on maximal agonist efficacy due to the less-than-complete inhibition of adenylyl cyclase by A3 AR agonists [16, 17]. The present study extended the previous one by using the newly synthesized enhancer LUF6000 and structurally diverse agonists and by testing the stimulation of GTPγS binding. It was found that in the current [35S]GTPγS binding assay system, none of the agonists (previously assumed to be full or partial agonists mainly based on a cyclic AMP functional assay) were fully efficacious, as the allosteric enhancer LUF6000 was able to enhance the Emax of all agonists used. Thus, the current [35S]GTPγS binding assay may represent the most suitable assay system as Hall suggested , since even highly efficacious agonists are unable to fully activate the signal transduction cascade. The observations from the present study are consistent with that predicted by Hall's model, and thus, the equations from Hall  were used to simulate various experimental curves from the present study and to derive conditions in which Emax and potency vary.
For the mathematical modeling, two independent parameters are necessary to simulate various effects on efficacy and potency. The binding cooperativity shifts the potency of the agonist. The activation coöperativity changes the Emax that the agonist can achieve, as well as the potency of the agonist. By contrast, the simple model of Ehlert for allosteric modulation  uses only one parameter to describe the property of allosteric modulation, so that it cannot simulate the current experimental results. The simple model of allosteric modulation can only generate curves with increased or decreased potency and efficacy at the same time.
As demonstrated in the present study, NECA is more efficacious than Cl-IB-MECA in stimulating G proteins as measured in the [35S]GTPγS binding assay. An explanation for the observation that LUF6000 has a much stronger effect on Cl-IB-MECA than on NECA derives from the mathematical modeling. NECA has a relatively strong intrinsic efficacy, such that the response is already close to the maximum response. Therefore, LUF6000 cannot enhance Emax much further.
LUF6000 showed a flexible modulatory effect of efficacy depending on the Emax of a given nucleoside derivative, being more effective for low-Emax agonists than for high- Emax agonists. The fact that LUF6000 did not show any effect on the basal receptor activity, yet showed an enhancement of agonist activity, suggests that such enhancers could be safer drugs than orthosteric agonists. The observations from the present study are consistent with the quantitative prediction using Hall's model. A simple explanation for the observation that LUF6000 has a much stronger effect on Cl-IB-MECA than on NECA derived from the mathematical modeling is that NECA has relatively strong intrinsic efficacy, such that the response is already close to the maximum response. Therefore, LUF6000 cannot enhance Emax much further. The finding that an antagonist of the A3 AR can be converted into an agonist may represent a novel mechanism of GPCR activation and may be generalized to other GPCRs.
Adenosine deaminase was obtained from Worthington Biochemical Corp. (Lakewood, NJ). NECA (adenosine-5' -N-ethyluronamide), CCPA (2-chloro-N6-cyclopentyladenosine) and Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)adenosine-5' -N-methyluronamide) were from Sigma (MO, USA). LUF6000 (N-(3,4-dichloro-phenyl)-2-cyclohexyl-1H-imidazo [4,5-c]quinolin-4-amine) and LUF5833 (2-aminophenyl-6-(1H-imidazol-2-ylmethylsulfanyl)-pyridine-3,5-dicarbonitrile) were synthesized at Leiden/Amsterdam Center for Drug Research (Leiden, The Netherlands). MRS541 (N6-(3-iodobenzyl)adenosine) and MRS542 (2-chloro-N6-(3-iodobenzyl)adenosine) were synthesized at NIDDK, National Institutes of Health (Bethesda, MD, USA). All compounds were stored at -20°C as DMSO solutions. DMSO was added to the controls in all experiments. [35S]GTPγS (1068 Ci/mmol) was from Amersham (Buckinghamshire, UK). All other compounds, reagents, or solutions were obtained from standard commercial sources and were of analytical grade.
Chinese hamster ovary (CHO) cells stably expressing A1 or A3 AR were maintained at 37°C with 5% CO2 in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 medium, supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 μg/mL streptomycin, and 2 mM glutamine.
[35S]GTPγS binding assay
The preparation of membranes from CHO cells stably expressing human A1 or A3 AR was as previously described . [35S]GTPγS binding was measured in 200 μl buffer containing 50 mM Tris HCl (pH 7.4), 1 mM EDTA, 1 mM MgCl2, 1 μM GDP, 1 mM dithiothreitol, 100 mM NaCl, 3 Units/ml adenosine deaminase, 0.2 nM [35S]GTPγS, 0.004% 3- [(3-cholamidopropyl) dimethylammonio]propanesulfonate (CHAPS), and 0.5% bovine serum albumin. Incubations were started by addition of the membrane suspension (5 μg protein/tube) to the test tubes, and carried out in duplicate for 30 min at 25°C. The reaction was stopped by rapid filtration through Whatman GF/B filters, pre-soaked in 50 mM Tris HCl, 5 mM MgCl2 (pH 7.4) containing 0.02% CHAPS. The filters were washed twice with 3 ml of the buffer mentioned before, and retained radioactivity was measured using liquid scintillation counting. Non-specific binding of [35S]GTPγS was measured in the presence of 10 μM unlabelled GTPγS.
Simulation of concentration-effect curves using MatLab
A mathematical model for allosteric modulation  was implemented in MatLab (version 7.1), a software package for technical computing. A graphic user interface was composed to facilitate parameter input and to yield output in the form of simulated curves.
Functional parameters were calculated using Prism 4.0 software (GraphPAD, San Diego, CA, USA). Data were expressed as mean ± sem. Student's t-test or ANOVA was used where appropriate for statistical analysis.
1,4-dihydro-2-methyl-6-phenyl-4-(phenylethynyl)-3,5-pyridinedicarboxylic acid, 3-ethyl 5-(phenylmethyl) ester
N- [9-chloro-2-(2-furanyl)[1,2,4]triazolo [1,5-c]quinazolin-5-yl]benzeneacetamide.
Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001, 53: 527-552.
Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG: ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006, 314: 1792-1795. 10.1126/science.1132559.
Jacobson KA, Gao ZG: Adenosine receptors as therapeutic targets. Nat Rev Drug Disc. 2006, 5: 247-264. 10.1038/nrd1983.
Yan L, Burbiel JC, Maass A, Müller CE: Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs. 2003, 8: 537-576. 10.1517/1472818.104.22.1687.
Gao ZG, Jacobson KA: Emerging adenosine receptor agonists. Expert Opin Emerging Drugs. 2007, 12: 479-492. 10.1517/1472822.214.171.1249.
Christopoulos A: Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Disc. 2002, 1: 198-210. 10.1038/nrd746.
Soudijn W, van Wijngaarden I, IJzerman AP: Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discov Today. 2004, 9: 752-758. 10.1016/S1359-6446(04)03220-9.
Birdsall NJM: Ligands interacting with G protein coupled receptors. Celltransmission. 2005, 20: 1-8.
Kenakin T: New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov. 2005, 4: 919-927. 10.1038/nrd1875.
Gao ZG, Jacobson KA: Allosterism in membrane receptors. Drug Discov Today. 2006, 11: 191-202. 10.1016/S1359-6446(05)03689-5.
Nagano N: Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther. 2006, 109: 339-365. 10.1016/j.pharmthera.2005.06.019.
Hoare SR: Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today. 2005, 10: 417-427. 10.1016/S1359-6446(05)03370-2.
Conn PJ, Battaglia G, Marino MJ, Nicoletti F: Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci. 2005, 6: 787-798. 10.1038/nrn1763.
Marino MJ, Conn PJ: Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol. 2006, 6: 98-102. 10.1016/j.coph.2005.09.006.
Gao ZG, Kim SK, IJzerman AP, Jacobson KA: Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem. 2005, 5: 545-553. 10.2174/1389557054023242.
Gao ZG, Kim SG, Soltysiak KA, Melman N, IJzerman AP, Jacobson KA: Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol. 2002, 62: 81-89. 10.1124/mol.62.1.81.
Göblyös A, Gao ZG, Brussee J, Connestari R, Santiago SN, Ye K, IJzerman AP, Jacobson KA: Structure-activity relationships of 1H-imidazo-[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. J Med Chem. 2006, 49: 3354-3361. 10.1021/jm060086s.
Lorenzen A, Lang H, Schwabe U: Activation of various subtypes of G-protein alpha subunits by partial agonists of the adenosine A1 receptor. Biochem Pharmacol. 1998, 56: 1287-1293. 10.1016/S0006-2952(98)00207-X.
Hall DA: Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol. 2000, 58: 1412-1423.
Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, Kim SG, Johnson CR, Jacobson KA: Structural determinants of A3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J Med Chem. 2002, 45: 4471-4484. 10.1021/jm020211+.
Kobilka BK: G protein coupled receptor structure and activation. Biochim Biophys Acta. 2007, 1768: 794-807. 10.1016/j.bbamem.2006.10.021.
Jakubík J, Bacáková L, Lisá V, el-Fakahany EE, Tucek S: Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci USA. 1997, 93: A8705-8709. 10.1073/pnas.93.16.8705.
Thomas EA, Carson MJ, Neal MJ, Sutcliffe JG: Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci USA. 1997, 94: 14115-14119. 10.1073/pnas.94.25.14115.
Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR: Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol. 2002, 61: 1297-1302. 10.1124/mol.61.6.1297.
Langmead CJ, Fry VA, Forbes IT, Branch CL, Christopoulos A, Wood MD, Herdon HJ: Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol. 2006, 69: 236-246.
Langmead CJ, Christopoulos A: Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci. 2006, 27: 475-481. 10.1016/j.tips.2006.07.009.
Kenakin T: Allosteric agonist modulators. J Recept Signal Transduct Res. 2007, 27: 247-259. 10.1080/10799890701509000.
Schwartz TW, Holst B: Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act?. Trends Pharmacol Sci. 2007, 28: 366-373. 10.1016/j.tips.2007.06.008.
Thor D, Schulz A, Hermsdorf T, Schöneberg T: Generation of an agonistic binding site for blockers of the M3 muscarinic acetylcholine receptor. Biochem J. 2008, 412: 103-112. 10.1042/BJ20071366.
Parker EM, Ross EM: Truncation of the extended carboxyl-terminal domain increases the expression and regulatory activity of the avian beta-adrenergic receptor. J Biol Chem. 1991, 266: 9987-9996.
Strader CD, Candelore MR, Hill WS, Dixon RA, Sigal IS: A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists. J Biol Chem. 1989, 264: 16470-16477.
Spalding TA, Burstein ES, Henderson SC, Ducote KR, Brann MR: Identification of a ligand-dependent switch within a muscarinic receptor. J Biol Chem. 1998, 273: 21563-21568. 10.1074/jbc.273.34.21563.
Claude PA, Wotta DR, Zhang XH, Prather PL, McGinn TM, Erickson LJ, Loh HH, Law PY: Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. Proc Natl Acad Sci USA. 1996, 93: 5715-5719. 10.1073/pnas.93.12.5715.
Joseph CG, Wang XS, Scott JW, Bauzo RM, Xiang Z, Richards NG, Haskell-Luevano C: tereochemical studies of the monocyclic agouti-related protein (103-122) Arg-Phe-Phe residues: conversion of a melanocortin-4 receptor antagonist into an agonist and results in the discovery of a potent and selective melanocortin-1 agonist. J Med Chem. 2004, 47: S6702-6710. 10.1021/jm0492756.
Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K: Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J Pharmacol Exp Ther. 2002, 301: 720-728. 10.1124/jpet.301.2.720.
Kourounakis A, Visser C, de Groote M, IJzerman AP: Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. Biochem Pharmacol. 2001, 61: 137-144. 10.1016/S0006-2952(00)00536-0.
Ehlert FJ: Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol. 1988, 33: 187-194.
This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. Kai Ye is supported by the Dutch Top Institute Pharma.
ZGG designed and carried out the pharmacological experiments and prepared the manuscript. KY performed the mathematical modeling. AG synthesized the allosteric enhancer LUF6000. IJAP and KAJ participated in design and coordination and helped to prepare the manuscript, and have given the approval of the final version to be published. All authors read and approved the final manuscript.
About this article
Cite this article
Gao, ZG., Ye, K., Göblyös, A. et al. Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacol 8, 20 (2008). https://doi.org/10.1186/1471-2210-8-20
- Adenosine Receptor
- Allosteric Modulator
- Adenosine Receptor Agonist
- Intrinsic Efficacy